Literature DB >> 21566653

Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

D K Walters1, X Wu, R C Tschumper, B K Arendt, P M Huddleston, K J Henderson, A Dispenzieri, D F Jelinek.   

Abstract

DNA double-strand breaks (DSBs) are deleterious lesions that can lead to chromosomal anomalies, genomic instability and cancer. The histone protein H2AX has an important role in the DNA damage response (DDR) and the presence of phospho-H2AXH2AX) nuclear foci is the hallmark of DSBs. We hypothesize that ongoing DNA damage provides a mechanism by which chromosomal abnormalities and intratumor heterogeneity are acquired in malignant plasma cells (PCs) in patients with multiple myeloma (MM). Therefore, we assessed PCs from patients with the premalignant condition, monoclonal gammopathy of undetermined significance (MGUS) and MM, as well as human MM cell lines (HMCLs) for evidence of DSBs. γH2AX foci were detected in 2/5 MGUS samples, 37/40 MM samples and 6/6 HMCLs. Notably, the DSB response protein 53BP1 colocalized with γH2AX in both MM patient samples and HMCLs. Treatment with wortmannin decreased phosphorylation of H2AX and suggests phosphoinositide (PI) 3-kinases and/or PI3-kinase-like family members underlie the presence of γH2AX foci in MM cells. Taken together, these data imply that ongoing DNA damage intensifies across the disease spectrum of MGUS to MM and may provide a mechanism whereby clonal evolution occurs in the monoclonal gammopathies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21566653      PMCID: PMC3940337          DOI: 10.1038/leu.2011.94

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  46 in total

1.  ATR and H2AX cooperate in maintaining genome stability under replication stress.

Authors:  Rebecca A Chanoux; Bu Yin; Karen A Urtishak; Amma Asare; Craig H Bassing; Eric J Brown
Journal:  J Biol Chem       Date:  2008-12-02       Impact factor: 5.157

2.  An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells.

Authors:  Aida Muslimovic; Ismail Hassan Ismail; Yue Gao; Ola Hammarsten
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

3.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

4.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

5.  Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks.

Authors:  Bunsyo Shiotani; Lee Zou
Journal:  Mol Cell       Date:  2009-03-13       Impact factor: 17.970

Review 6.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

7.  Impaired NHEJ function in multiple myeloma.

Authors:  Clara Yang; Christopher Betti; Sheetal Singh; Amir Toor; Andrew Vaughan
Journal:  Mutat Res       Date:  2008-11-05       Impact factor: 2.433

8.  Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

Authors:  Enrique M Ocio; Patricia Maiso; Xi Chen; Mercedes Garayoa; Stela Alvarez-Fernández; Laura San-Segundo; David Vilanova; Lucía López-Corral; Juan C Montero; Teresa Hernández-Iglesias; Enrique de Alava; Carlos Galmarini; Pablo Avilés; Carmen Cuevas; Jesús F San-Miguel; Atanasio Pandiella
Journal:  Blood       Date:  2008-11-19       Impact factor: 22.113

Review 9.  GammaH2AX and cancer.

Authors:  William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier
Journal:  Nat Rev Cancer       Date:  2008-11-13       Impact factor: 60.716

Review 10.  Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin.

Authors:  Andrea Kinner; Wenqi Wu; Christian Staudt; George Iliakis
Journal:  Nucleic Acids Res       Date:  2008-09-04       Impact factor: 16.971

View more
  38 in total

1.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Authors:  David A Alagpulinsa; Srinivas Ayyadevara; Shmuel Yaccoby; Robert J Shmookler Reis
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

Review 2.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

3.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

4.  A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.

Authors:  David Abasiwani Alagpulinsa; Shmuel Yaccoby; Srinivas Ayyadevara; Robert Joseph Shmookler Reis
Journal:  Cancer Biol Ther       Date:  2015-05-21       Impact factor: 4.742

5.  CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.

Authors:  Denise K Walters; Bonnie K Arendt; Diane F Jelinek
Journal:  Cell Cycle       Date:  2013-09-03       Impact factor: 4.534

Review 6.  γ-H2AX and other histone post-translational modifications in the clinic.

Authors:  Christophe E Redon; Urbain Weyemi; Palak R Parekh; Dejun Huang; Allison S Burrell; William M Bonner
Journal:  Biochim Biophys Acta       Date:  2012-03-09

7.  Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.

Authors:  Jagannath Pal; Mariateresa Fulciniti; Puru Nanjappa; Leutz Buon; Yu-Tzu Tai; Pierfrancesco Tassone; Nikhil C Munshi; Masood A Shammas
Journal:  Cancer Genomics Proteomics       Date:  2012 Mar-Apr       Impact factor: 4.069

8.  Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation.

Authors:  B K Arendt; D K Walters; X Wu; R C Tschumper; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2012-03-30       Impact factor: 11.528

9.  microRNA-34a promotes DNA damage and mitotic catastrophe.

Authors:  Alexander V Kofman; Jungeun Kim; So Yeon Park; Evan Dupart; Christopher Letson; Yongde Bao; Kai Ding; Quan Chen; David Schiff; James Larner; Roger Abounader
Journal:  Cell Cycle       Date:  2013-09-19       Impact factor: 4.534

10.  Immunofluorescence Microscopy of γH2AX and 53BP1 for Analyzing the Formation and Repair of DNA Double-strand Breaks.

Authors:  Henning D Popp; Susanne Brendel; Wolf-Karsten Hofmann; Alice Fabarius
Journal:  J Vis Exp       Date:  2017-11-03       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.